Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents

Volume: 37 Number: 3 September 1, 2011
  • Ediz Dalkılıç
  • Nihan Alkış
  • Güven Özkaya
  • Mahmut Yavuz
  • Mustafa Güllülü
  • Kamil Dilek
  • Alpaslan Ersoy
  • Ayşe Nur Bayındır
  • Mustafa Yurtkuran
  • Ayşe Çefle
Journal of Uludağ University Medical Faculty Cover
Journal of Uludağ University Medical Faculty
PDF Download
EN TR

Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents

Abstract

In this study, we evaluated the efficiency and safety of rituximab (RIT) treatment in patients with rheumatoid arthritis(RA) who were ina-dequate responders to anti tumor necrosis alpha (antiTNFα) agents or patients that can not tolerate antiTNFα agents because of adverse events. Twenty two patients with RA were enrolled to the study. Disease activity score(DAS 28) before and after (3. month) the RIT treat-ment, acute phase reactants, number of antiTNFα agents before RIT therapy and adverse events were analysed. Rheumatoid factor was positive in 18 of the 22 patients. Seventeen of the 22 patients were inadequate responders to antiTNFα agents, 2 patients developed malig-nancy and in 3 patients antiTNFα agents could not be used due to other adverse events. In cross sectional analysis of the 3. month, a signifi-cant decrease was seen in DAS28 from 5,9 to 4,8 (n=15, p

Keywords

Details

Primary Language

English

Subjects

-

Journal Section

-

Authors

Ediz Dalkılıç This is me

Nihan Alkış This is me

Güven Özkaya This is me

Mahmut Yavuz This is me

Mustafa Güllülü This is me

Kamil Dilek This is me

Alpaslan Ersoy This is me

Ayşe Nur Bayındır This is me

Mustafa Yurtkuran This is me

Ayşe Çefle This is me

Publication Date

September 1, 2011

Submission Date

September 1, 2011

Acceptance Date

-

Published in Issue

Year 2011 Volume: 37 Number: 3

IZ

https://izlik.org/JA39CE68SE

Cite

RIS / Bibtex
APA
Dalkılıç, E., Alkış, N., Özkaya, G., Yavuz, M., Güllülü, M., Dilek, K., Ersoy, A., Bayındır, A. N., Yurtkuran, M., & Çefle, A. (2011). Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents. Journal of Uludağ University Medical Faculty, 37(3), 127-130. https://izlik.org/JA39CE68SE
AMA
1.Dalkılıç E, Alkış N, Özkaya G, et al. Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents. Journal of Uludağ University Medical Faculty. 2011;37(3):127-130. https://izlik.org/JA39CE68SE
Chicago
Dalkılıç, Ediz, Nihan Alkış, Güven Özkaya, et al. 2011. “Rituximab Efficacy and Safety in Patients With Rheumatoid Arthritis That Are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents”. Journal of Uludağ University Medical Faculty 37 (3): 127-30. https://izlik.org/JA39CE68SE.
EndNote
Dalkılıç E, Alkış N, Özkaya G, Yavuz M, Güllülü M, Dilek K, Ersoy A, Bayındır AN, Yurtkuran M, Çefle A (September 1, 2011) Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents. Journal of Uludağ University Medical Faculty 37 3 127–130.
IEEE
[1]E. Dalkılıç et al., “Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents”, Journal of Uludağ University Medical Faculty, vol. 37, no. 3, pp. 127–130, Sept. 2011, [Online]. Available: https://izlik.org/JA39CE68SE
ISNAD
Dalkılıç, Ediz - Alkış, Nihan - Özkaya, Güven - Yavuz, Mahmut - Güllülü, Mustafa - Dilek, Kamil - Ersoy, Alpaslan - Bayındır, Ayşe Nur - Yurtkuran, Mustafa - Çefle, Ayşe. “Rituximab Efficacy and Safety in Patients With Rheumatoid Arthritis That Are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents”. Journal of Uludağ University Medical Faculty 37/3 (September 1, 2011): 127-130. https://izlik.org/JA39CE68SE.
JAMA
1.Dalkılıç E, Alkış N, Özkaya G, Yavuz M, Güllülü M, Dilek K, Ersoy A, Bayındır AN, Yurtkuran M, Çefle A. Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents. Journal of Uludağ University Medical Faculty. 2011;37:127–130.
MLA
Dalkılıç, Ediz, et al. “Rituximab Efficacy and Safety in Patients With Rheumatoid Arthritis That Are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents”. Journal of Uludağ University Medical Faculty, vol. 37, no. 3, Sept. 2011, pp. 127-30, https://izlik.org/JA39CE68SE.
Vancouver
1.Ediz Dalkılıç, Nihan Alkış, Güven Özkaya, Mahmut Yavuz, Mustafa Güllülü, Kamil Dilek, Alpaslan Ersoy, Ayşe Nur Bayındır, Mustafa Yurtkuran, Ayşe Çefle. Rituximab Efficacy and Safety in Patients with Rheumatoid arthritis That are Refractory or Intolerable to Anti Tumor Necrosis Factor Alpha Agents. Journal of Uludağ University Medical Faculty [Internet]. 2011 Sep. 1;37(3):127-30. Available from: https://izlik.org/JA39CE68SE

ISSN: 1300-414X, e-ISSN: 2645-9027

Creative Commons License
Journal of Uludag University Medical Faculty is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2023